Prostate Studies
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

A Phase 2 Study of Sipuleucel-T With or Without Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-Metastatic Castrate-Resistant Prostate Cancer
More Information

Phase II Trial of Pembrolizumab (MK-3475) in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Chemotherapy (KEYNOTE-199)
More Information

A Phase 3 Randomized, Placebo-Controlled Double-Blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
More Information

A Single-Arm, Phase II Study to Evaluate the Safety and Efficacy of VT-464 in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
More Information

Comprehensive Genetic Characterization of Intraprostatic Chronic Inflammation and Prostate Cancer in
African American Men

Taste in Prostate Cancer

A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic
Men with Castration Resistant Metastatic Prostate Cancer: The TRANSFORMER Trial
More Information

A Phase II Open-Label, Parallel Group Study of Abiraterone Acetate Plus Prednisone in African-American and Caucasian Men with Metastatic Castration-Resistant Prostate Cancer
More Information

GU 115
A Double-Blinded, Placebo-Controlled, Randomized Phase II Trial of Enzalutamide With or Without the PI3 Kinase/m TOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer

More Information

UAB 1336
A Phase 2 Trial of Carfilzomib for Metastatic Castration-Resistant Prostate Cancer Following Chemotherapy and Androgen Pathway Inhibitors
More Information

A Phase I Study of a Prostate-Specific Membrane Antigen Targeting-Tubulysin Conjugate EC1169 in Patients With Recurrent Metastatic, Castration-Resistant Prostate Cancer (mCRPC)
More Information

Radium-223 Alpha Emitter Agent in Safety Study in mCRPC Population for Long-Term Evaluation
More Information

Sotio SP005
A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
More Information


A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer (PREDICT)
More Information

RTOG 0924
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy In Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
More Information

TUHC 07/25/13 - Genetics of Prostate Cancer

BAY 15396

A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)
More Information

SWOG S1216

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
More Information

1430 Tulane Ave, New Orleans, LA 70112